BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22078471)

  • 1. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease.
    Martinez CA; Shah S; Shearer WT; Rosenblatt HM; Paul ME; Chinen J; Leung KS; Kennedy-Nasser A; Brenner MK; Heslop HE; Liu H; Wu MF; Hanson IC; Krance RA
    J Allergy Clin Immunol; 2012 Jan; 129(1):176-83. PubMed ID: 22078471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloablative transplantation using either cord blood or bone marrow leads to immune recovery, high long-term donor chimerism and excellent survival in chronic granulomatous disease.
    Tewari P; Martin PL; Mendizabal A; Parikh SH; Page KM; Driscoll TA; Malech HL; Kurtzberg J; Prasad VK
    Biol Blood Marrow Transplant; 2012 Sep; 18(9):1368-77. PubMed ID: 22326631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic Reduced-Intensity Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease: a Single-Center Prospective Trial.
    Parta M; Kelly C; Kwatemaa N; Theobald N; Hilligoss D; Qin J; Kuhns DB; Zerbe C; Holland SM; Malech H; Kang EM
    J Clin Immunol; 2017 Aug; 37(6):548-558. PubMed ID: 28752258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
    Güngör T; Teira P; Slatter M; Stussi G; Stepensky P; Moshous D; Vermont C; Ahmad I; Shaw PJ; Telles da Cunha JM; Schlegel PG; Hough R; Fasth A; Kentouche K; Gruhn B; Fernandes JF; Lachance S; Bredius R; Resnick IB; Belohradsky BH; Gennery A; Fischer A; Gaspar HB; Schanz U; Seger R; Rentsch K; Veys P; Haddad E; Albert MH; Hassan M;
    Lancet; 2014 Feb; 383(9915):436-48. PubMed ID: 24161820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen.
    Parta M; Shah NN; Baird K; Rafei H; Calvo KR; Hughes T; Cole K; Kenyon M; Schuver BB; Cuellar-Rodriguez J; Zerbe CS; Holland SM; Hickstein DD
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1250-1259. PubMed ID: 29412158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total body irradiation-free haploidentical peripheral blood stem cell transplantation compared to related and unrelated donor transplantation in pediatrics with acute lymphoblastic leukemia.
    Mardani M; Behfar M; Jafari L; Mohseni R; Naji P; Salajegheh P; Donyadideh G; Hamidieh AA
    Pediatr Blood Cancer; 2023 May; 70(5):e30255. PubMed ID: 36815626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth.
    Soncini E; Slatter MA; Jones LB; Hughes S; Hodges S; Flood TJ; Barge D; Spickett GP; Jackson GH; Collin MP; Abinun M; Cant AJ; Gennery AR
    Br J Haematol; 2009 Apr; 145(1):73-83. PubMed ID: 19222467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-Transplantation Cyclophosphamide-Based Haploidentical versus Matched Unrelated Donor Peripheral Blood Hematopoietic Stem Cell Transplantation Using Myeloablative Targeted Busulfan-Based Conditioning for Pediatric Acute Leukemia.
    Hong KT; Park HJ; Kim BK; An HY; Choi JY; Kang HJ
    Transplant Cell Ther; 2022 Apr; 28(4):195.e1-195.e7. PubMed ID: 35021131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience.
    Morillo-Gutierrez B; Beier R; Rao K; Burroughs L; Schulz A; Ewins AM; Gibson B; Sedlacek P; Krol L; Strahm B; Zaidman I; Kalwak K; Talano JA; Woolfrey A; Fraser C; Meyts I; Müller I; Wachowiak J; Bernardo ME; Veys P; Sykora KW; Gennery AR; Slatter M
    Blood; 2016 Jul; 128(3):440-8. PubMed ID: 27216217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of allogeneic hematopoietic stem cell transplantation for chronic granulomatous disease in children: A multicentre, retrospective cohort study in China.
    Si Y; Dou Y; Zhai X; Zhou C; Lu W; Meng Y; Qian X; Chen J; Wang P; Luo C; Yu J; Tang X
    Clin Immunol; 2024 Mar; 260():109919. PubMed ID: 38309448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matched Family versus Alternative Donor Hematopoietic Stem Cell Transplantation for Patients with Thalassemia Major: Experience from a Tertiary Referral Center in South India.
    Swaminathan VV; Uppuluri R; Patel S; Ravichandran N; Ramanan KM; Vaidhyanathan L; Ramakrishnan B; Jayakumar I; Raj R
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1326-1331. PubMed ID: 32200123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic haematopoietic stem cell transplantation as therapy for chronic granulomatous disease--single centre experience.
    Goździk J; Pituch-Noworolska A; Skoczeń S; Czogała W; Wędrychowicz A; Baran J; Krasowska-Kwiecień A; Wiecha O; Zembala M
    J Clin Immunol; 2011 Jun; 31(3):332-7. PubMed ID: 21384251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A comparative study of unrelated donor and matched-sibling donor allogeneic hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia].
    Zhou J; Fu YW; Liang LJ; Wang Q; Han LJ; Zu YL; Zhang Y; Zhu XH; Yu FK; Fang BJ; Wei XD; Song YP
    Zhonghua Nei Ke Za Zhi; 2016 Dec; 55(12):927-931. PubMed ID: 27916046
    [No Abstract]   [Full Text] [Related]  

  • 16. Triple-Drug Graft-versus-Host Disease Prophylaxis after HLA-Matched Unrelated Donor Nonmyeloablative Allogenic Hematopoietic Stem Cell Transplantation.
    Wegener A; Andersen NS; Friis LS; Petersen SL; Schjødt I; Kornblit B; Sengeløv H; Gjærde LK
    Transplant Cell Ther; 2023 Sep; 29(9):575.e1-575.e6. PubMed ID: 37301257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
    Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.
    Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
    Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.